You are here

  • Home
  • Archive
  • Volume 14, Issue 1
  • Intravitreal ranibizumab for the management of serous maculopathy secondary to optic disc coloboma-associated choroidal neovascularisation

Article Text

Article menu
Download PDFPDF
Case report
Intravitreal ranibizumab for the management of serous maculopathy secondary to optic disc coloboma-associated choroidal neovascularisation
  1. Sarah Schimansky1,
  2. Xia Ni Wu2,
  3. Catherine Egan2,3 and
  4. Quresh Mohamed4
  1. 1Department of Ophthalmology, Royal United Hospitals Bath NHS Foundation Trust, Bath, UK
  2. 2Medical Retina, Moorfields Eye Hospital NHS Foundation Trust, London, UK
  3. 3Faculty of Brain Sciences, University College London Institute of Ophthalmology, London, UK
  4. 4Department of Ophthalmology, Gloucestershire Hospitals NHS Foundation Trust, Cheltenham, UK
  1. Correspondence to Dr Sarah Schimansky; sarah.schimansky{at}nhs.net

Abstract

We report the case of a 19-year-old patient with symptomatic unilateral serous maculopathy associated with an optic nerve coloboma. Fluorescein angiography detected a focal late leak at the temporal edge of the coloboma which was later found to correspond with an area of choroidal neovascularisation on optical coherence tomography angiography. A course of intravitreal ranibizumab achieved good clinical and structural response. This report contributes to the evidence that maculopathies associated with cavitary optic nerve anomalies may in some instances result from choroidal neovascularisation. It also highlights the importance of angiography to identify potential choroidal neovascular membranes, particularly in the absence of haemorrhages and neovascular membranes on fundus examination and conventional optical coherence tomography.

  • macula
  • eye
  • therapeutic indications

https://doi.org/10.1136/bcr-2020-235452

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors SS and QM conceived and designed the study. SS drafted the manuscript. SS, XNW, CE and QM were involved in this patient’s care, the acquisition, analysis and interpretation of data, and the critical revision of the manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient consent for publication Obtained.

    • Provenance and peer review Not commissioned; externally peer reviewed.